The same group subsequently reported that combining MYC status with patient level radiomic features (MTV, SUV metrics and dissemination features) in 323 patients from three clinical trials in aggressive B cell lymphoma improved the positive predictive value (PPV) compared with the IPI and IPI combined with MYC status, again supporting a role for radiomic analysis.4 The gene discussed is MYC; the disease is B-cell non-Hodgkin lymphoma.